Both miR-22 treatment and Gal-1 siRNA significantly reduced the tumor Load, as measured by the liver-to-body weight ratio, to 9% compared with 30% in the untreated control group (Fig. 3B). This evidence concerns the gene LGALS1 and neoplasm.